Abstract
To review key findings and insights from the Steno 2 trial involving 160 patients with type 2 diabetes in Denmark. The Steno 2 study design, with conventional and intensive treatment arms, is described, and the outcomes are summarized. Intensive and target-driven behavior modeling and polypharmacy for 7.8 years induced an absolute risk reduction of 20% in cardiovascular disease events in patients with type 2 diabetes and the metabolic syndrome in comparison with a conventional multifactorial treatment. The relative risk reduction found for microvascular events after 4 years was maintained at a similar level after 7.8 years of intervention: nephropathy 61%, retinopathy 58%, and autonomic neuropathy 63%. Improving glycemic control in patients with type 2 diabetes may be as important as, or even more important than, treating hypertension and dyslipidemia for the prevention of both microvascular and macrovascular complications, particularly when aggressive treatment is initiated at an early stage of the disease.
Citations
Jun 10, 2010·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·J G Garweg, A Wenzel
Aug 31, 2006·Diabetes Technology & Therapeutics·N G LessanS Athamneh
Apr 7, 2009·Diabetes Technology & Therapeutics·Stephan MartinVolker Lodwig
Mar 7, 2008·Journal of Women's Health·Jeffrey P Levine
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Giuseppe Derosa, Sibilla At Salvadeo
Dec 6, 2011·Maturitas·Ronald PyramLisel Loney-Hutchinson
May 23, 2013·Diabetic Medicine : a Journal of the British Diabetic Association·D Yu, D Simmons
Apr 22, 2015·Obesity Surgery·Alper CelikBahri Onur Celik
Apr 1, 2015·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Francisco ArrietaUNKNOWN Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED)
Jun 3, 2015·Atencion primaria·Francisco ArrietaUNKNOWN Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED)
Jul 1, 2014·Atencion primaria·Beatriz Pascual de la PisaUNKNOWN investigadores del estudio DESIDIAB 1
Mar 16, 2016·BMJ Open·Alper CelikSurendra Ugale
Aug 28, 2016·Obesity Surgery·Alper CelikYunus Emre Kılıç
Jul 12, 2016·Biomarker Insights·Shariq I SherwaniMeena K Sakharkar
Aug 2, 2011·Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquée, Nutrition Et Métabolisme·Michael C Riddell, Jamie Burr
Sep 19, 2014·World Journal of Clinical Cases·Juan J ChillarónJuan Pedro-Botet
Nov 28, 2019·Diabetic Medicine : a Journal of the British Diabetic Association·E CagiltayM Abdul-Ghani
Jul 7, 2017·Obesity Surgery·Serdar YormazMustafa Sahin
May 1, 2007·Expert Review of Endocrinology & Metabolism·Vladimir SkljarevskiKeri A Kles
Feb 1, 2015·The Cochrane Database of Systematic Reviews·Diana V DoRobert N Frank
Jun 12, 2013·Postgraduate Medicine·Agata PtaszynskaJames List
Jan 9, 2021·Diabetes Technology & Therapeutics·Sara HallströmMarcus Lind
Dec 16, 2021·Revista da Associação Médica Brasileira·Ingrid Mendonça LourençoDaniela Bassi-Dibai